Takeda Pharmaceutical (NYSE:TAK) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a strong sell rating in a research report report published on Thursday morning,Zacks.com reports.

Takeda Pharmaceutical Stock Up 1.3%

Shares of NYSE TAK opened at $15.5030 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. The stock has a market capitalization of $49.33 billion, a PE ratio of 51.68 and a beta of 0.22. The stock’s fifty day simple moving average is $14.80 and its two-hundred day simple moving average is $14.69. Takeda Pharmaceutical has a 12-month low of $12.80 and a 12-month high of $15.56.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, analysts expect that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at $28,000. FNY Investment Advisers LLC purchased a new stake in shares of Takeda Pharmaceutical during the 1st quarter valued at $37,000. Evelyn Partners Investment Management LLP lifted its holdings in shares of Takeda Pharmaceutical by 163.4% during the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock valued at $39,000 after purchasing an additional 1,560 shares during the last quarter. NewSquare Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 182.4% during the 2nd quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.